Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750074 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4GRM2CHRNA3CHRNA7 | |
| SCHEMBL27585110 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL32685326 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL28027837 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL28028484 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL30896087 | 0.81 | GRM2 (0.41) | CHRNB2CHRNA4GRM2LMNA | |
| SCHEMBL13301353 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA3CHRNA7 | |
| SCHEMBL28219902 | 0.80 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL16115213 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL28006536 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008178-A1 | KRAS G12D INHIBITOR AND APPLICATION THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2024-01-11 | — | — | WO | disclosed |
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| CN-115135647-A | Pesticidally active fused bicyclic heteroaromatic amino compounds | 先正达农作物保护股份公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115023420-A | Pesticidally active fused bicyclic heteroaromatic compounds | 先正达农作物保护股份公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-115003666-A | Pesticidally active fused bicyclic heteroaromatic amino compounds | 先正达农作物保护股份公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114630825-A | Pesticidally active fused bicyclic heteroaromatic compounds | 先正达农作物保护股份公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086703-A1 | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, CERS2 | CHRNB2 3669/4885CHRNA4 4317/4885GRM2 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.